COVID-19 infection in patients with intestinal failure: UK experience.


Journal

JPEN. Journal of parenteral and enteral nutrition
ISSN: 1941-2444
Titre abrégé: JPEN J Parenter Enteral Nutr
Pays: United States
ID NLM: 7804134

Informations de publication

Date de publication:
08 2021
Historique:
revised: 05 02 2021
received: 03 12 2020
accepted: 09 02 2021
pubmed: 16 2 2021
medline: 10 9 2021
entrez: 15 2 2021
Statut: ppublish

Résumé

The direct effect of the coronavirus disease 2019 (COVID-19) pandemic on patients with intestinal failure (IF) has not been described. We conducted a nationwide study of UK IF centers to evaluate the infection rates, presentations, and outcomes in patients with types 2 and 3 IF. A total of 45 patients with IF contracted COVID-19 between March and August 2020; this included 26 of 2191 (1.2%) home parenteral nutrition (HPN)-dependent adults and 19 of 298 (6.4%) adults hospitalized with type 2 IF. The proportion of patients receiving nursing care for HPN administration was higher in those with community-acquired COVID-19 (66.7%) than the proportion in the entire HPN cohort (26.1%; P < .01). Two HPN-dependent and 1 hospitalized patient with type 2 IF died as a direct consequence of the virus (6.7% of 45 patients with types 2 or 3 infected). This is the first study to describe the outcomes of COVID-19 in a large cohort of patients requiring long-term PN. Methods to reduce hospital and community nosocomial spread would likely be beneficial.

Sections du résumé

BACKGROUND
The direct effect of the coronavirus disease 2019 (COVID-19) pandemic on patients with intestinal failure (IF) has not been described.
METHODS
We conducted a nationwide study of UK IF centers to evaluate the infection rates, presentations, and outcomes in patients with types 2 and 3 IF.
RESULTS
A total of 45 patients with IF contracted COVID-19 between March and August 2020; this included 26 of 2191 (1.2%) home parenteral nutrition (HPN)-dependent adults and 19 of 298 (6.4%) adults hospitalized with type 2 IF. The proportion of patients receiving nursing care for HPN administration was higher in those with community-acquired COVID-19 (66.7%) than the proportion in the entire HPN cohort (26.1%; P < .01). Two HPN-dependent and 1 hospitalized patient with type 2 IF died as a direct consequence of the virus (6.7% of 45 patients with types 2 or 3 infected).
CONCLUSION
This is the first study to describe the outcomes of COVID-19 in a large cohort of patients requiring long-term PN. Methods to reduce hospital and community nosocomial spread would likely be beneficial.

Identifiants

pubmed: 33586170
doi: 10.1002/jpen.2087
pmc: PMC8013499
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1369-1375

Informations de copyright

© 2021 The Authors. Journal of Parenteral and Enteral Nutrition published by Wiley Periodicals LLC on behalf of American Society for Parenteral and Enteral Nutrition.

Références

JPEN J Parenter Enteral Nutr. 2021 Aug;45(6):1369-1375
pubmed: 33586170
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Clin Nutr. 2016 Apr;35(2):247-307
pubmed: 26944585
Clin Nutr. 2020 Jul;39(7):1988-1991
pubmed: 32487434
JPEN J Parenter Enteral Nutr. 2021 Jan;45(1):43-49
pubmed: 33241555
Infect Control Hosp Epidemiol. 2020 Aug;41(8):982-983
pubmed: 32279676

Auteurs

P J Allan (PJ)

Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

T Ambrose (T)

Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

C Mountford (C)

Department of Gastroenterology, Freeman Hospital, Newcastle, UK.

A Bond (A)

Department of Gastroenterology, Royal Liverpool and Broadgreen Hospitals, Liverpool, UK.

C Donnellan (C)

St James' and Leeds Gastroenterology Institute, St James' Hospital, Leeds, UK.

R Boyle (R)

Department of Biochemistry, Aberdeen Royal Infirmary, Aberdeen, UK.

C Calvert (C)

Department of Gastroenterology, Royal Devon and Exeter Hospital, Exeter, UK.

E Cernat (E)

Department of Paediatric Gastroenterology, Leeds General Infirmary, Leeds, UK.

E Clarke (E)

Department of Gastroenterology, Southampton University Hospital, Southampton, UK.

S C Cooper (SC)

GI Medicine, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

S Donnelly (S)

Leonard Jones' Intestinal Rehabilitation Unit, St Mark's Hospital, Harrow, UK.

B Evans (B)

Department of Gastroenterology, Bristol Royal Infirmary, Bristol, UK.

M Glynn (M)

Centre for Digestive Diseases, Royal London Hospital, London, UK.

R Hewett (R)

Department of Gastroenterology, University of Wales Hospital, Cardiff, UK.

A S Holohan (AS)

Nutrition, Leicester Royal Infirmary, Leicester, UK.

E F Leitch (EF)

Intestinal Failure Surgery, Glasgow Royal Infirmary, Glasgow, UK.

J Louis-Auguste (J)

Department of Gastroenterology, St George's, London, UK.

S Mehta (S)

Intestinal Failure Unit, University College London Hospitals, London, UK.

S Naik (S)

Department of Paediatric Gastroenterology, Royal London Children's Hospital, London, UK.

J Nightingale (J)

St Mark's Hospital, Harrow, London.

G Rafferty (G)

Department of Gastroenterology, Belfast City Hospital, Belfast, UK.

A Rodrigues (A)

Department of Paediatric Gastroenterology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

L Sharkey (L)

Intestinal Failure and Transplant, Cambridge University Hospitals, Cambridge, UK.

M Small (M)

Leonard Jones' Intestinal Rehabilitation Unit, St Mark's Hospital, Harrow, UK.

A Teubner (A)

Intestinal Failure Unit, Salford Royal Hospital, Salford, UK.

A Urs (A)

Paediatric Gastroenterology, Sheffield Children's Hospital, Sheffield, UK.

N Wyer (N)

Intestinal Failure and Nutrition Support, University Hospitals Coventry and Warwickshire, Coventry, UK.

S Lal (S)

Intestinal Failure Unit, Salford Royal Hospital, Salford, UK.
Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and Manchester Academic Health Sciences Centre, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH